News

The renewed federal panel aims to improve vaccine oversight and restore public trust amid declining immunization rates and ongoing concerns about vaccine ingredients.

C difficile carriers faced a higher baseline risk for hospital-onset infection compared to non-carriers, and this risk was not significantly influenced by antibiotic use.

Doxycycline postexposure prophylaxis is associated with emerging tetracycline resistance in Neisseria gonorrhoeae and commensal organisms, highlighting the need for cautious, targeted use.

This week, predictive microbiome models for C difficile, synergistic antibiotic strategies for E faecalis, to pharmacy-led hepatitis C care, and more.

Pranita Tamma, MD, MHS, continues her conversation about a study she was involved in that compared ceftolozane-tazobactam and ceftazidime-avibactam. She discusses the usage of inverse probability weighting with propensity scores to balance patient groups and limit bias.

The comprehensive program provides instruction in both specialties to enable fellows to treat the most critically ill patients.

The FDA announces two voluntary recalls so far in August 2025 for Camembert and Brie cheeses sold in multiple states and NYC.

As virus season begins, Leilani Valdes, MD, MBA, FCAP, highlights the lab’s role in early detection and the importance of informed, respectful dialogue on vaccines.

A recent literature review describes the current state of artificial intelligence tools for guiding antimicrobial therapy. Are you ready for change?

Robert Bransfield, MD, discusses how microbes may influence violent behavior and global instability through biological and environmental pathways.

A preventable crisis, measles, makes a dangerous comeback.

Ty Stoner of Walgreens Specialty Pharmacy on navigating barriers, building partnerships, and improving access for vulnerable populations.

Jose Alexander, MD, offers insights on these antimicrobial combinations when treating against this bacterium.

Pathologist Leilani Valdes, MD, MBA, FCAP, explains the role of PCR testing, early surveillance, and vaccine education in protecting community health.

A new study finds that personalized gut microbiome models may predict C difficile colonization risk and guide targeted probiotic treatment.

If this GSK antibiotic is approved, it will provide a new oral option to patients in the US who are currently relying on injectable treatments.

A multi-prong approach reduces inappropriate antibiotic prescribing to outpatients with upper respiratory tract infection.

Sharon Nachman, MD, breaks down the latest on Stratus and Nimbus variants and what families should consider as schools resume.

Emily Olsen, PhD, offers some insights on this underdiagnosed infection, including describing antimicrobial studies, particularly in biofilm and intracellular environments. Her findings look to create a standardized approach for treating all forms of the different presentations of bartonellosis.

Vir initiates phase 2b head-to-head trial of novel combination therapy vs bulevirtide.

Pediatric infectious disease expert Sharon Nachman, MD, explains how to identify symptoms, assess travel risk, and prevent mosquito-borne illness in kids.

This week, from synthetic biosecurity concerns to gaps in maternal hepatitis C screening, rising COVID cases, antimicrobial resistance, fast-tracked CF therapies, and more.

After a three-month review, the FDA and EMA have cleared continued use of IXCHIQ in adults 60+, adding new safety warnings for elderly individuals with chronic conditions.

CDC found 6.9% of those testing positive for Candida auris colonization on skin develop invasive infection, and calls for better surveillance and prevention.

Cost-effectiveness of COVID-19 vaccination in older adults amid rising US cases and limited booster access.

China's largest recorded chikungunya outbreak prompts strict mosquito control and mandatory hospitalization in Foshan.

Despite updated guidelines for universal hepatitis C virus screening in pregnancy, testing rates remain well below targets, missing chances to prevent perinatal transmission.

Results from a recent study comparing ceftolozane-tazobactam and ceftazidime-avibactam for difficult-to-treat Pseudomonas aeruginosa infections found no statistically significant difference in resistance emergence but a surprising numerical trend favoring ceftazidime-avibactam. Pranita Tamma, MD, MHS, continues her conversation about this topic.

Low vaccine uptake, immunity gaps, and new antiviral data raise alarms ahead of a potential late-summer surge.

Clarametyx Biosciences said its investigational antibody therapy, CMTX-101, which is in a phase 1b/2a study, remains on track for full trial enrollment by the end of 2025.